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Maximizing the Return from
Genome Research*
Thomas G. Field, Jr.**
Only fourteen years ago, the U.S. Supreme Court was asked to find
the fruits of genetic research unpatentable: 1
... The briefs present a gruesome parade of horribles.
Scientists, among them Nobel laureates, are quoted
suggesting that genetic research may pose a serious
threat to the human race.... We are told that genetic
research... may spread pollution and disease, ... result in
a loss of genetic diversity, and... tend to depreciate the
value of human life. These arguments are forcefully,
even. passionately, presented; they remind us that, at
times, human ingenuity seems unable to control fully
the forces it creates - that with Hamlet, it is sometimes
better "to bear those ills we have than fly to others that
we know not of."
The Court concluded that such arguments were best addressed to
Congress. Congressional failure to take the action urged upon the
Court, coupled with major support for the human genome project,
* Earlier versions of most papers appearing here were presented at a July 1993
conference. Gianna Julian-Arnold, J.D., M.I.P., then a Research Fellow at Franklin
Pierce Law Center (FPLC), played a critical role in organizing it. Also, the
Department of Energy played a critical role in covering, e.g., the expenses of several
speakers. Also, with regard to this symposium, Timothy S. Odykirk, J.D., and others
named on the inside front cover made important contributions.
** Professor of Law, FPLC. H6 received his A.B. (Chemistry) and J.D. from West
Virginia University and LL.M. (Trade Regulation) from New York University.
I Diamond v. Chakrabarty 447 U.S. 303, 315 (1980). See also, Animal Legal
Defense Fund v. Quigg, 18 U.S.P.Q.2d 1677 (Fed. Cir. 1991).
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Biotechnonics and Society.... (1991), reviewed 3 Risk 185 (1992); The Code of
Codes: Scientific and Social Issues in the Human Genome Project, (Daniel J. Kevles
and Leroy Hood eds. 1992), reviewed 3 Risk 261 (1993) and Elaine Draper, Risky
Business: Genetic Testing and Exdusionary Practices in the Hazardous Workplace
(1991), reviewed 3 Risk 267 (1993).
5 Risk Health, Safety & Environment 95 [Spring 1994]
seems to indicate, e.g., belief that potential benefits outweigh potential
hazards and that inappropriate uses of genetic technology can be
foreclosed as they arise. 2 The last is buttressed by considering, e.g.,
that, as copyrights do not permit sale of obscene books, patents do not
permit illegal uses of inventions - nor is one engaged in forbidden
types of research apt to admit it in a patent application. Thus, these
papers reflect a shift to R&D policy management to achieve positive
health, safety and environmental objectives.
As Dr. Cook-Deegan notes in the lead article, 3 we lack
knowledge that may be necessary to fine tune the intellectual property
system. 4 Yet, these papers may make some things clearer to people
unfamiliar with intellectual property or private and public technology
transfer, e.g., that private firms will not invest in R&D, or anything
else, without confidence of being able to recoup their investments when
they succeed. The symposium should therefore be useful in other
attempts to fashion public incentives for private firms to contribute to
reducing the risks of natural and artificial hazards. 5
2 Those interested in more integration of ethical and intellectual property issues
should consider The Genetic Frontier: Ethics, Law and Policy (Mark S. Frankel &
Albert Teich, eds. 1994) - a 259 pp. paperback published by AAA Press in January
($22.95) - also containing papers by Dr. Cook-Deegan and Dr. Murashige.
3 Infra, at 118.
4 See generally, Industrial Innovation: Joint Hearings Before the Senate Comm. on
Commerce, Science and Transportation, and Select Comm. on Small Business, and
House Comms. on Science and Technology, and Small Business, 96th Cong., 1st
Sess., Parts 1 and 2 (1979). As part of a lively exchange, Dr. Frank Press stated, "For
25 years the question of innovation and Americans' ability to innovate has been...
around; it's been studied to death." Part 1, at 40. This suggests too much; see, e.g., J.
G. Tewksbury et al., Measuring the Societal Benefits of Innovation, 209 Science 658
(1980) "A sample which was as representative as possible... would have been
desirable.... [I]nformation... was so difficult to obtain that availability of data became
dominant in the selection of cases."
5 For example, just before these papers went to press, The Greening of
Technology Transfer..., another FPLC conference considered how best to use
intellectual property and technology transfer in global pursuit of biodiversity and
environmental goals.
